MCUJF Stock UPDATES Medicure Inc (MCUJF) 2.5663 08/10/2014 2

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Medicure Inc (MCUJF) 2.5663 $MCUJF

Medicure Announces Shares for Debt Settlement
Marketwire - Fri Jul 11, 1:59PM CDT
Medicure Inc. (the "Company" (TSX VENTURE: MPH)(OTCQB: MCUJF) announces today that the Company, subject to all necessary regulatory approvals, has entered into shares for debt agreements with its Chief Executive Officer, Dr. Albert Friesen and certain members of the Board of Directors, pursuant to which the Company will issue 205,867 of its common shares at a deemed price of $1.98 per common share to satisfy $407,616.66 of outstanding amounts owing to Dr. Friesen and members of the Company's Board of Directors. These shares will be subject to resale restrictions for a period of four months from the date of issuance under applicable securities legislation.

Medicure Announces Grant of Options
Marketwire - Mon Jul 07, 3:31PM CDT
Medicure Inc. (the "Company" (TSX VENTURE: MPH)(OTCQB: MCUJF) announces today that its Board of Directors has approved the grant of an aggregate of 332,300 options to certain directors, officers, employees, management company employees and consultants of the Company pursuant to the Company's Stock Option Plan. Of these options, 92,300 are set to expire on the tenth anniversary of the date of grant, and 240,000 are set to expire on the fifth anniversary of the date of grant. All 332,300 options were issued at an exercise price of $1.90 per share. The options are subject to the approval of the TSX Venture Exchange.

Medicure Acquires Minority Position in Pharmaceutical Manufacturer, Apicore
Marketwire - Thu Jul 03, 7:38AM CDT
Medicure Inc. ("Medicure" or the "Company" (TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today announced that the Company and its newly formed and wholly owned subsidiary, Medicure U.S.A. Inc. ("Medicure USA" have entered into an arrangement whereby they have acquired a minority interest in a pharmaceutical manufacturing business. Specifically, Medicure and Medicure USA have acquired a 6.09% equity interest (5.33% on a fully-diluted basis) (the "Ownership Interest" in two newly formed holding companies of which Apicore LLC and Apicore US LLC (collectively, "Apicore" will be wholly owned operating subsidiaries. Medicure also received an option to acquire all of the remaining issued shares of Apicore LLC and the holding company of Apicore US LLC, within the next 3 years. The Ownership Interest and certain other rights, including the Option Rights described below, were obtained by Medicure for its lead role in structuring a US$22.5 million, majority interest purchase and financing of Apicore (the "Purchase" by Signet Healthcare Partners ("Signet" , Knight Therapeutics Inc. (TSX: GUD) ("Knight" , and investors affiliated with Sanders Morris Harris Inc. ("Sanders" (collectively, the "Investors" .

Knight Therapeutics Inc. Signs Secured Debt Financing Agreement to Support the Acquisition of Apicore
Marketwire - Thu Jul 03, 7:21AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight" , a leading Canadian specialty pharmaceutical company, announced today that it has entered into a secured debt agreement to support the acquisition of two newly formed holding companies of which Apicore LLC and Apicore US LLC (collectively, "Apicore" will be wholly owned operating subsidiaries. The purchase arrangement included a secured loan provided by Knight and Sanders Morris Harris Inc., and an equity investment by Signet Healthcare Partners ("Signet" for an aggregate amount of US$22.5 million. Medicure Inc. ("Medicure" acquired a minority interest in Apicore and the founding shareholders of Apicore continue to own a significant minority interest in Apicore.

Medicure Reports Financial Results for the Third Quarter Fiscal 2014
Marketwire Canada - Wed Mar 26, 4:11PM CDT
Medicure Inc. ("Medicure" or the "Company" (TSX VENTURE:MPH) (OTCQB:MCUJF), a specialty pharmaceutical company, today reported its results from operations for the quarter ended February 28, 2014.

Medicure Inc. - Product Pipeline Review - 2013
M2 - Tue Mar 18, 4:00AM CDT
Summary

Innovative Food Holdings, Inc. Presents at MicroCapClub Invitational
Marketwire - Tue Feb 04, 7:45AM CST
Innovative Food Holdings, Inc. (OTCQB: IVFH) announced today it has been selected to present at the 2nd annual MicroCapClub Invitational.

Medicure Reports Second Quarter Financial Results for Fiscal 2014
Marketwire - Tue Jan 28, 3:31PM CST
Medicure Inc. ("Medicure" or the "Company" (TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today reported its results from operations for the second quarter ended November 30, 2013.

Beer in Hungary
M2 - Wed Jan 22, 3:28AM CST
After a difficult period for the beer industry in Hungary caused by the negative effects of the economic crisis on consumer purchasing power, the decline in beer consumption started to turn around in 2011 and in 2012, beer sales continued to grow in both value and volume terms. Volume sales surpassed 700 million litres, but this is still a long way from the volume sales of five years ago. Due to stable demand by beer consumers further recovery is expected.

Beer in India
M2 - Wed Jan 22, 3:28AM CST
Beer sales posted a growth of 11% in terms of total volume, spurred by a hot summer of 2012 and rising prices of competing liquor like spirits and wine. In addition, a crackdown by state governments on illegal spirits and country liquor also caused a shift to branded beer.

SarlaFlex Inc. Closes $13 Million in NMTC Financing for New U.S. Facility
Marketwire - Fri Jan 17, 8:35AM CST
SarlaFlex Inc. has secured $13 million in New Markets Tax Credit (NMTC) allocation from Los Angeles-based National New Markets Fund, LLC (NNMF) to redevelop a manufacturing facility in rural South Carolina into the company's first U.S. based yarn and thread plant. U.S. Bank serves as the tax credit investor, capitalizing the allocation.

Acute Coronary Syndrome - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t22wlp/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H2 2013" report to their offering. 'Acute Coronary Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Coronary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome. Scope - A snapshot of the global therapeutic scenario for Acute Coronary Syndrome. - A review of the Acute Coronary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Coronary Syndrome pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. AstraZeneca PLC GlaxoSmithKline plc Pfizer Inc. Bayer AG Ligand Pharmaceuticals Incorporated Medicure Inc. Arena Pharmaceuticals, Inc. CSL Limited LG Life Sciences, Ltd Auspex Pharmaceuticals Viron Therapeutics, Inc. Regado Biosciences. Cerenis Therapeutics SA Lacer, S.A. Lee's Pharmaceutical Holdings Limited Ampio Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/t2...e_coronary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 127

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 5

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 271

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 13

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 71

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 30

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 292

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
Skanska Adds $80M U.S. Tech Facility Contract to Orders

Updated Category News Views 107

An $80 million add-on is the sort of construction news that looks modest until you remember what it says about the customer relationship. Skanska has won an additional contract from an existing client for a U.S. tech facility, worth roughly SEK 760 million, and it will enter U.S. order bookings in the fourth quarter of 2026. No fireworks, no grand strategic...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 165

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 107

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading

Top 5 Most Recently Viewed Articles

Prinses Máxima Center Enhances Genomics with Callisto™ Innovation

Updated Category News Views 300

Prinses Máxima Center's Partnership with Volta Labs The Prinses Máxima Center for Pediatric Oncology is making headlines with its recent acquisition of the Callisto™ platform from Volta Labs. This major step forward aims to enhance efficiency in sample preparation across a variety of genomics workflows, specifically designed for both Illumina and Oxford Nanopore...

Continue Reading
Keros Therapeutics to Showcase Innovations at Key Conferences

Updated Category News Views 152

Exciting Participation of Keros Therapeutics in Major Conferences Keros Therapeutics, Inc. is making significant strides in the biopharmaceutical landscape by focusing on innovative therapies targeting disorders associated with the TGF-ß family of proteins. Recently, the company announced that its Chair and Chief Executive Officer, Jasbir S. Seehra, Ph.D., will represent...

Continue Reading
KULR Technology Unveils Major Licensing Breakthrough with Japan

Updated Category News Views 133

KULR Technology Group, Inc. (NYSE American: KULR) unveiled a major licensing agreement back in 2024 that had traders buzzing. This $2.35 million deal centered around their vibration reduction technology, known as KULR Xero Vibe (KXV). At first glance, it seemed like a solid step for the company into new markets, but let’s peel back the layers and see what's really...

Continue Reading
Mainz Biomed Achieves Significant Milestones and Results

Updated Category News Views 204

Mainz Biomed Reports Financial Results and Strategic Progress Lab network revenue up by 33% year-over-year. Operating loss down by 30% and net loss by 18%. Partnerships driving innovation and growth forward. Highlighting 2025 accomplishments and future goals. Mainz Biomed N.V. (NASDAQ: MYNZ), a pioneering molecular genetics diagnostic firm, has reported its financial...

Continue Reading
PioCreat Launches Innovative Mini Dental 3D Printer During Expo

Updated Category News Views 247

PioCreat Launches Innovative Mini Dental 3D Printer at Moscow Event PioCreat, a well-respected name in the 3D printing sector, made a significant impression at the dental industry's notable event, the 2025 Moscow Dental Expo. This gathering, renowned for showcasing advancements in digital dentistry, took place at Crocus-Expo IEC, attracting a wide array of international...

Continue Reading